Scullion Jane E
University Hospitals of Leicester Glenfield Site, Institute for Lung Health, Leicester, UK.
Int J Chron Obstruct Pulmon Dis. 2007;2(1):33-40. doi: 10.2147/copd.2007.2.1.33.
Anticholinergics have been used to treat obstructive respiratory disease for many years from historical preparations of the deadly nightshade genus, to the more recent developments ofipratropium, oxitropium, and tiotropium. The medical treatment of airways obstruction has focused on achieving maximal airway function through bronchodilators. Of the two main bronchodilators, beta2-agonists are often the first treatment choice although there is evidence of equivalence and some suggestions of the superiority of anticholinergics in chronic obstructive pulmonary disease (COPD). The following review looks at the background of anticholinergics, their pharmacological properties, and the evidence for use with suggestions for their place in the treatment of COPD.
多年来,抗胆碱能药物一直用于治疗阻塞性呼吸道疾病,从致命茄属植物的历史制剂,到最近开发的异丙托溴铵、氧托溴铵和噻托溴铵。气道阻塞的医学治疗一直致力于通过支气管扩张剂实现最大气道功能。在两种主要的支气管扩张剂中,β2受体激动剂通常是首选治疗药物,尽管有证据表明两者等效,并且有一些迹象表明抗胆碱能药物在慢性阻塞性肺疾病(COPD)中更具优势。以下综述将探讨抗胆碱能药物的背景、其药理学特性以及使用证据,并就其在COPD治疗中的地位提出建议。